Pharmaceutical and Healthcare disease pipeline guide Resistant Hypertension-Pipeline Review, H2 2016- Ken Research


Latest Pharmaceutical and Healthcare disease pipeline guide Resistant Hypertension-Pipeline Review, H2 2016, provides an overview of the Resistant Hypertension (Cardiovascular) pipeline landscape.

Resistant hypertension is defined as high blood pressure that remains uncontrolled despite treatment with antihypertensive agents. Causes of resistant hypertension include abnormalities in the hormones that control blood pressure, accumulation of artery-clogging plaque in blood vessels, obesity and sleep problems. This is handled by lifestyle alterations and regular medications.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Resistant Hypertension-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Resistant Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Resistant Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Resistant Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1 and 1 respectively.

Resistant Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


The pipeline guide provides a snapshot of the global therapeutic landscape of Resistant Hypertension (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Resistant Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Resistant Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Resistant Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Resistant Hypertension (Cardiovascular)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Resistant Hypertension (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Resistant Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Topics Covered In the Report

  • Resistant Hypertension Pipeline Market
  • Resistant Hypertension Pipeline Market Research report
  • Resistant Hypertension Pipeline Review
  • Resistant Hypertension Therapeutics under Development
  • Pipeline Products for Resistant Hypertension Overview
  • Resistant Hypertension Dormant Projects
  • Resistant Hypertension Discontinued Products
  • Resistant Hypertension Pipeline Review industry
  • Resistant Hypertension Pipeline by Novartis
  • Resistant Hypertension Therapeutic Products under Development
  • Key Players in Resistant Hypertension Therapeutics
  • Resistant Hypertension Pipeline Assessment
  • Resistant Hypertension Pipeline Overview
  • Resistant Hypertension Pipeline Products

To know more on coverage:

Contact Us:

Ken Research

Ankur Gupta, Head Marketing & Communications


Comments are closed.